Business
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)
AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancem
About this update from Lantern Pharma Inc.
[{"type":"image","alt":"InvestorBrandNetwork (IBN)","displaySize":"","headline":null,"caption":"InvestorBrandNetwork (IBN)","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/0a75ed90c9546495e45b8a96c60d10bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fUCiYWRAsZ4cB0BZl4MQrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0a75ed90c9546495e45b8a96c60d10bd","width":300,"height":169}},"lazy":false},{"type":"text","content":"AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.","length":371,"tagName":"p"},{"type":"text","content":"The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Panna Sharma, President, CEO, and Director of Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform. Mr. Sharma explains the mechanisms of the drug and also provides insights into the three ongoing clinical trials for each of the potential drug-candidates that could be worth several billion USD each.","length":561,"tagName":"p"},{"type":"text","content":"During the interview, Sharma explained Lantern Pharma’s core mission and AI-driven approach.","length":92,"tagName":"p"},{"type":"text","content":"“We like to think of ourselves as an AI-first company focused on creating cancer medicines. The problem that we’re trying to solve is a massive problem globally: about $250 billion a year is spent on research and development into new cancer medicines, yet it takes 10-to-12 years to go from an idea to an approved drug, and 93% of them fail… To me, this is a perfect problem area for top cancer minds to try to use AI, big data and computational biology to solve. That’s what our team does.”","length":491,"tagName":"p"},{"type":"text","content":"“We’re maniacally focused on driving AI first. We’ve created computational models from t...